Dr. Reddy's Laboratories Limited Investigation
Company: Dr. Reddy's Laboratories Limited
Ticker: (NYSE) RDY
See If You Qualify For Monetary Reward
Join the Dr. Reddy's Laboratories Limited Investigation
Investigation Details
On July 22, 2026, Dr. Reddy’s Laboratories shares fell approximately 9% after the Company reported a Q1 FY27 earnings miss and disclosed a 2.4 billion provision tied to out-of-spec semaglutide batches.
On the related call, Chief Executive Officer Erez Israeli stated there was “no impact on the product’s existing global regulatory filings” and “no patient-safety impact associated with product already supplied to the market.” The same update followed Dr. Reddy’s prior statements highlighting semaglutide approvals and launches, including Obeda in Canada and oral semaglutide approval in India.
The investigation concerns whether investors were adequately informed about the semaglutide batch issue, the related provision, and the financial exposure before RDY shares declined approximately 9%.